Comparison Overview

Parexel

VS

MENARINI Group

Parexel

541 Church at North Hills St, 1000, Raleigh, North Carolina, US, 27609
Last Update: 2026-01-17
Between 750 and 799

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 20,434
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
1

MENARINI Group

Via dei Sette Santi 1/3, Firenze, 50131, IT
Last Update: 2026-01-17
Between 750 and 799

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,720
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/parexel.jpeg
Parexel
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Parexel
100%
Compliance Rate
0/4 Standards Verified
MENARINI Group
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Parexel in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MENARINI Group in 2026.

Incident History — Parexel (X = Date, Y = Severity)

Parexel cyber incidents detection timeline including parent company and subsidiaries

Incident History — MENARINI Group (X = Date, Y = Severity)

MENARINI Group cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/parexel.jpeg
Parexel
Incidents

Date Detected: 10/2025
Type:Vulnerability
Blog: Blog
https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
Incidents

No Incident

FAQ

Parexel company demonstrates a stronger AI Cybersecurity Score compared to MENARINI Group company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Parexel company has historically faced a number of disclosed cyber incidents, whereas MENARINI Group company has not reported any.

In the current year, MENARINI Group company and Parexel company have not reported any cyber incidents.

Neither MENARINI Group company nor Parexel company has reported experiencing a ransomware attack publicly.

Neither MENARINI Group company nor Parexel company has reported experiencing a data breach publicly.

Neither MENARINI Group company nor Parexel company has reported experiencing targeted cyberattacks publicly.

Parexel company has disclosed at least one vulnerability, while MENARINI Group company has not reported such incidents publicly.

Neither Parexel nor MENARINI Group holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Parexel company nor MENARINI Group company has publicly disclosed detailed information about the number of their subsidiaries.

Parexel company employs more people globally than MENARINI Group company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Parexel nor MENARINI Group holds SOC 2 Type 1 certification.

Neither Parexel nor MENARINI Group holds SOC 2 Type 2 certification.

Neither Parexel nor MENARINI Group holds ISO 27001 certification.

Neither Parexel nor MENARINI Group holds PCI DSS certification.

Neither Parexel nor MENARINI Group holds HIPAA certification.

Neither Parexel nor MENARINI Group holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Backstage is an open framework for building developer portals, and @backstage/backend-defaults provides the default implementations and setup for a standard Backstage backend app. Prior to versions 0.12.2, 0.13.2, 0.14.1, and 0.15.0, the `FetchUrlReader` component, used by the catalog and other plugins to fetch content from URLs, followed HTTP redirects automatically. This allowed an attacker who controls a host listed in `backend.reading.allow` to redirect requests to internal or sensitive URLs that are not on the allowlist, bypassing the URL allowlist security control. This is a Server-Side Request Forgery (SSRF) vulnerability that could allow access to internal resources, but it does not allow attackers to include additional request headers. This vulnerability is fixed in `@backstage/backend-defaults` version 0.12.2, 0.13.2, 0.14.1, and 0.15.0. Users should upgrade to this version or later. Some workarounds are available. Restrict `backend.reading.allow` to only trusted hosts that you control and that do not issue redirects, ensure allowed hosts do not have open redirect vulnerabilities, and/or use network-level controls to block access from Backstage to sensitive internal endpoints.

Risk Information
cvss3
Base: 3.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:L/I:N/A:N
Description

Backstage is an open framework for building developer portals, and @backstage/cli-common provides config loading functionality used by the backend and command line interface of Backstage. Prior to version 0.1.17, the `resolveSafeChildPath` utility function in `@backstage/backend-plugin-api`, which is used to prevent path traversal attacks, failed to properly validate symlink chains and dangling symlinks. An attacker could bypass the path validation via symlink chains (creating `link1 → link2 → /outside` where intermediate symlinks eventually resolve outside the allowed directory) and dangling symlinks (creating symlinks pointing to non-existent paths outside the base directory, which would later be created during file operations). This function is used by Scaffolder actions and other backend components to ensure file operations stay within designated directories. This vulnerability is fixed in `@backstage/backend-plugin-api` version 0.1.17. Users should upgrade to this version or later. Some workarounds are available. Run Backstage in a containerized environment with limited filesystem access and/or restrict template creation to trusted users.

Risk Information
cvss3
Base: 6.3
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:N/A:N
Description

Backstage is an open framework for building developer portals. Multiple Scaffolder actions and archive extraction utilities were vulnerable to symlink-based path traversal attacks. An attacker with access to create and execute Scaffolder templates could exploit symlinks to read arbitrary files via the `debug:log` action by creating a symlink pointing to sensitive files (e.g., `/etc/passwd`, configuration files, secrets); delete arbitrary files via the `fs:delete` action by creating symlinks pointing outside the workspace, and write files outside the workspace via archive extraction (tar/zip) containing malicious symlinks. This affects any Backstage deployment where users can create or execute Scaffolder templates. This vulnerability is fixed in `@backstage/backend-defaults` versions 0.12.2, 0.13.2, 0.14.1, and 0.15.0; `@backstage/plugin-scaffolder-backend` versions 2.2.2, 3.0.2, and 3.1.1; and `@backstage/plugin-scaffolder-node` versions 0.11.2 and 0.12.3. Users should upgrade to these versions or later. Some workarounds are available. Follow the recommendation in the Backstage Threat Model to limit access to creating and updating templates, restrict who can create and execute Scaffolder templates using the permissions framework, audit existing templates for symlink usage, and/or run Backstage in a containerized environment with limited filesystem access.

Risk Information
cvss3
Base: 7.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:N/A:L
Description

FastAPI Api Key provides a backend-agnostic library that provides an API key system. Version 1.1.0 has a timing side-channel vulnerability in verify_key(). The method applied a random delay only on verification failures, allowing an attacker to statistically distinguish valid from invalid API keys by measuring response latencies. With enough repeated requests, an adversary could infer whether a key_id corresponds to a valid key, potentially accelerating brute-force or enumeration attacks. All users relying on verify_key() for API key authentication prior to the fix are affected. Users should upgrade to version 1.1.0 to receive a patch. The patch applies a uniform random delay (min_delay to max_delay) to all responses regardless of outcome, eliminating the timing correlation. Some workarounds are available. Add an application-level fixed delay or random jitter to all authentication responses (success and failure) before the fix is applied and/or use rate limiting to reduce the feasibility of statistical timing attacks.

Risk Information
cvss3
Base: 3.7
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N
Description

The Flux Operator is a Kubernetes CRD controller that manages the lifecycle of CNCF Flux CD and the ControlPlane enterprise distribution. Starting in version 0.36.0 and prior to version 0.40.0, a privilege escalation vulnerability exists in the Flux Operator Web UI authentication code that allows an attacker to bypass Kubernetes RBAC impersonation and execute API requests with the operator's service account privileges. In order to be vulnerable, cluster admins must configure the Flux Operator with an OIDC provider that issues tokens lacking the expected claims (e.g., `email`, `groups`), or configure custom CEL expressions that can evaluate to empty values. After OIDC token claims are processed through CEL expressions, there is no validation that the resulting `username` and `groups` values are non-empty. When both values are empty, the Kubernetes client-go library does not add impersonation headers to API requests, causing them to be executed with the flux-operator service account's credentials instead of the authenticated user's limited permissions. This can result in privilege escalation, data exposure, and/or information disclosure. Version 0.40.0 patches the issue.

Risk Information
cvss3
Base: 5.3
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:H/I:N/A:N